Shield Therapeutics plc

STX.L · LSE
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-£21,272-£33,293-£28,662-£19,678
Dep. & Amort.£1,115£1,071£2,332£2,207
Deferred Tax£0£0£0£1,759
Stock-Based Comp.£0£875£912£1,339
Change in WC£12,584-£7,024£3,186-£1,793
Other Non-Cash£567£1,245£3,984-£572
Operating Cash Flow-£7,007-£37,126-£18,247-£16,738
Investing Activities
PP&E Inv.-£1,895-£239-£1,895-£2,064
Net Acquisitions£0£0£0£0
Inv. Purchases£0£0£0£0
Inv. Sales/Matur.£0£0£0£0
Other Inv. Act.£0-£2,191£200£13
Investing Cash Flow-£1,895-£2,430-£1,695-£2,051
Financing Activities
Debt Repay.£4,461£23,998£9,080£0
Stock Issued-£87£26,817£87£37,392
Stock Repurch.£0£0-£82£0
Dividends Paid£0£0£0£0
Other Fin. Act.-£167-£1,159-£1,378-£9,808
Financing Cash Flow£4,207£49,656£7,707£27,584
Forex Effect-£639£446£2,939£382
Net Chg. in Cash-£5,333£10,546-£9,296£9,177
Supplemental Information
Beg. Cash£10,941£3,402£12,117£2,940
End Cash£5,608£13,948£2,821£12,117
Free Cash Flow-£7,034-£40,074-£20,142-£18,802